Bruker takes a step to Korea

In Drug Discovery by Simon Crompton-ReidLeave a Comment

Bruker Corp. and the Graduate School of Analytical Science and Technology (GRAST) at Chungnam National University will collaborate to advance the field of glycomics and its applications in the rapidly growing biopharmaceutical industry in the Republic of Korea. This collaboration adds to the growing number of partnerships and industry linkage projects which Bruker has fostered with the scientific communities of Asia Pacific, the company notes.

Under their collaboration agreement, the GRAST team, led by Prof. Hyun Joo An, and the Glycomics Applications Development Group at Bruker, led by Dr. Detlev Suckau, will jointly develop MALDI-TOF-based methodologies targeting the analysis of glycans. MALDI-TOF refers to combining a matrix-assisted laser desorption-ionization source with a time-of-flight mass analyzer and is considered a soft ionization technique which allows the analysis of biopolymers such as DNA, proteins, peptides and sugars, which tend to be fragile and fragment when ionized by more conventional methods. It is similar in character to electrospray ionization (ESI) both in relative softness and the ions produced.

The purpose of these studies will be to create a better understanding of the function of glycans in biomolecules and their key role in many biological processes—an undertaking of considerable complexity. The partners will target much of their efforts toward the development of specific methods and software applications that can be utilized in the development and quality control of biosimilar pharmaceutical products, such as therapeutic antibodies.

Iman El-Hariry, Vice President, Clinical Research, Synta Pharmaceuticals, USA, would be presenting at Drug Discovery World Asia 2012 this March on "Discovering Modern personalised medicine with innovative biomarkers".

Click here to register your attendance at this conference now.

Leave a Comment

Current ye@r *